Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date

The IL-17/IL-23 axis is now understood to influence psoriasis, and the development of novel IL-17 inhibitor medications marks a sea change in the treatment of psoriasis. Brodalumab is a recombinant, fully human immunoglobulin IgG2 monoclonal antibody specifically targeted against IL-17RA. This artic...

Descripción completa

Detalles Bibliográficos
Autores principales: Galluzzo, M, D’Adamio, S, Massaro, A, Piccolo, A, Bianchi, L, Talamonti, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6503649/
https://www.ncbi.nlm.nih.gov/pubmed/31118733
http://dx.doi.org/10.2147/CCID.S165605

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6503649/
https://www.ncbi.nlm.nih.gov/pubmed/31118733
http://dx.doi.org/10.2147/CCID.S165605

Ejemplares similares